We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that,...
Cassava Sciences Short Term - We look to Sell at 32.45 (stop at 36.81) We look to sell rallies. Trading volume is increasing. Previous support, now becomes resistance at 32.00. We can see no technical reason for a change of trend. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 12.45 and 7.56...
SAVA is currently trading in a critical support zone. It just established it's first "higher low" since it's crash from $100. Further upward movement from here would likely lead to a test of $60. Downward movement, below $37, could prove disastrous. SAVA has established a "higher low" two other times since late 2020, both leading to large bull moves and a rumored...
Not a Financial Advisor. SAVA Recently pulled back from newer highs at $70 I see potential to get up to $86- $92 over the course of the next couple of weeks. I believe this to be a solid entry point for those shopping around. I see SAVA on its ways to reach new highs on a Mid term level trading plan. Recent news around their phase 3 starting. SAVA will...
Idea for Cassava Sciences (SAVA): - Decoded: PVVol: - H&S pattern, Distribution UTAD with Exhaustion gap (Price). - High Volume sell (Volume). - > 5x ATR (Vol). - 4.236 Fib. - ML Diamond. PT: 36 Time: By Sept 8, but add 0.3 bars margin (Sept 27) SL: 2.4N~ 128.38 GLHF - DPT
The CEO Remi Barber lately teased a possible partnership which will be announced within the next weeks. This could have a huge impact on the SP of Cassava Sciences. As a consequence we might see a new ATH soon!
$SAVA (Cassava Sciences) saw an insane rally in 2021 from $7 to $145 on the hopes that its groundbreaking Alzheimer's treatment will yield promising results never before seen in the history of the disease. Currently there are no Alzheimer's modifying therapies on the market and if the data surrounding Cassava's main drug, simufilam, is accurate then it could be...
It's interesting to see what happens after plotting out fib lines sometimes. SAVA , for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some...
ESPERAR AL RECHAZO DE LAS MEDIAS PARA ENTRAR.
The stock NASDAQ:SAVA is consolidating in a triangle and shows relative strength in the past few days. It might happen soon, that the stock will break through the upper boundary of the triangle which will lead the way towards 11$ and later also 15$.